(ANTI-HER2 ANTIBODY)-DRUG CONJUGATE - DAIICHI SANKYO CO LTD

Title:

(ANTI-HER2 ANTIBODY)-DRUG CONJUGATE

Document Type and Number:

WIPO Patent Application WO/2015/155976

Kind Code:

A1

Abstract:

As an anti-tumor drug having an excellent anti-tumor effect and excellent safety and also having an excellent therapeutic effect, an antibody-drug conjugate is provided, said conjugate being characterized by being produced by linking an anti-tumor compound represented by formula (1) to an anti-HER2 antibody through a linker having a structure represented by the formula: L1-L2-LP-NH-(CH2)n1-La-Lb-Lc- or the formula: -L1-L2-LP- (in the conjugate, the anti-HER2 antibody is bound at the terminal of L1, and the anti-tumor compound is bound at the terminal of Lc or LP wherein a nitrogen atom in an amino group located at position-1 in the anti-tumor compound serves as a binding site).

Inventors:

NAITO HIROYUKI (JP)
MASUDA TAKESHI (JP)
NAKADA TAKASHI (JP)
YOSHIDA MASAO (JP)
ASHIDA SHINJI (JP)
MIYAZAKI HIDEKI (JP)
KASUYA YUJI (JP)
MORITA KOJI (JP)
OGITANI YUSUKE (JP)
ABE YUKI (JP)

Application Number:

PCT/JP2015/001922

Publication Date:

October 15, 2015

Filing Date:

April 06, 2015

Export Citation:

Click for automatic bibliography generation Help

Assignee:

DAIICHI SANKYO CO LTD (JP)

International Classes:

C07K16/32; A61K31/4745; A61K39/395; A61P35/00; C07K5/072; C07K5/083; C07K5/103; C07K7/06

Domestic Patent References:

WO2002000734A1	2002-01-03
WO2014057687A1	2014-04-17
WO2014061277A1	2014-04-24

Foreign References:

JP2009538629A	2009-11-12
JP2008521828A	2008-06-26
JP2005511627A	2005-04-28
JP2012509259A	2012-04-19
JP2013500253A	2013-01-07
JPH1192405A	1999-04-06
JPH1095802A	1998-04-14

Other References: